Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate targeting HER2 but paradoxically efficient even in breast cancers expressing HER2 at very low levels. Here authors show that invasive ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

AnkA and Abl-1 are crucial for A. phagocytophilum infection, as depletion of AnkA enzymatic activity by antibody binding or silencing of Abl-1 inhibits pathogen colonization of mammalian cells. [23] ...